KDR (Kinase Insert Domain Receptor), also known as Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), is a receptor tyrosine kinase that serves as the primary signaling receptor for VEGF-mediated angiogenesis and vascular development. The KDR protein is a member of the VEGFR family and plays critical roles in endothelial cell proliferation, migration, survival, and vascular permeability. In the nervous system, KDR regulates neurovascular coupling, maintains blood-brain barrier (BBB) integrity, and provides neurotrophic support to neurons[1].
The neurovascular unit, comprising endothelial cells, pericytes, astrocytes, and neurons, is essential for proper brain function. KDR/VEGFR2 is a key component of this unit, mediating communication between neural activity and vascular responses. Dysregulation of KDR signaling has been implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), stroke, and other neurological disorders[2]. Understanding KDR's role in neurovascular function provides insights into disease mechanisms and therapeutic opportunities.
The human KDR gene is located on chromosome 4q12 and spans approximately 44 kilobases. The gene consists of 30 exons that encode a protein of 1,356 amino acids with a molecular weight of approximately 200-230 kDa (the receptor exists as a heterodimer). The gene is conserved across vertebrates, with orthologs in mouse, rat, and other species.
The KDR/VEGFR2 protein contains several functional domains:
KDR functions as a homodimer upon VEGF binding:
KDR/VEGFR2 is the major VEGF signaling receptor for vascular processes[3]:
Angiogenesis:
Endothelial cell activation:
Vascular permeability:
KDR plays crucial roles in the neurovascular unit[1:1]:
Neurovascular coupling:
Blood-brain barrier:
Cerebral angiogenesis:
KDR activates multiple major signaling pathways:
| Pathway | Function | Key Effectors |
|---|---|---|
| PI3K/AKT | Survival, NO production | eNOS, Akt, mTOR |
| MAPK/ERK | Proliferation | MEK, ERK1/2 |
| PLCγ-PKC | Calcium signaling | PKC isoforms |
| Src | Vascular permeability | VE-cadherin, FAK |
| p38 | Stress responses | MAPKAPK-2 |
KDR exhibits specific expression patterns in the nervous system:
KDR is expressed throughout the brain with notable levels in:
KDR expression is regulated by:
KDR is significantly implicated in AD pathophysiology[5]:
Neurovascular dysfunction:
Blood-brain barrier breakdown:
Angiogenesis impairment:
Amyloid and tau interaction:
In PD, KDR plays important roles[8]:
Substantia nigra vasculature:
Neurovascular coupling defects:
Neuroprotection potential:
Stroke:
Retinopathy:
Glioblastoma:
KDR activates multiple downstream pathways:
PI3K/AKT pathway:
MAPK/ERK pathway:
PLCγ-PKC pathway:
Src pathway:
KDR interacts with other components of the neurovascular unit:
KDR specifically binds VEGF-A isoforms:
KDR is a major therapeutic target[11]:
For Alzheimer's disease:
For Parkinson's disease:
Zhang W, Yan W, Dong L, et al. VEGF signaling in neurovascular development and function in the central nervous system. Cellular and Molecular Life Sciences. 2020. ↩︎ ↩︎
Iadecola C. Neurovascular coupling in the aging brain: new insights into the pathogenesis of neurodegeneration. Alzheimer's & Dementia. 2017. ↩︎
Cleaver O, Melton M, D'Amore P, et al. Endothelial signaling during development: VEGF and notch in vascular patterning. Developmental Biology. 2019. ↩︎
Tajes M, Ramos-Fernandez E, Waseem M, et al. The blood-brain barrier: structure, function, and therapeutic targeting. Neurobiology of Disease. 2020. ↩︎
Engler L, Fallieris A, Amouyel P, et al. VEGF and neurodegeneration: the dual role of vascular endothelial growth factor in Alzheimer's disease. Brain Research Bulletin. 2018. ↩︎
Peckys DB, MacDonald AJ, Jonaitis T, et al. Endothelial alterations in Alzheimer's disease brain. Acta Neuropathologica. 2019. ↩︎
Yang J, Park OJ, Kim S, et al. VEGF-mediated blood-brain barrier dysfunction in neurodegenerative diseases. Journal of Neuroinflammation. 2020. ↩︎
Cao L, Wang Z, Liu F, et al. VEGF receptor 2 signaling in Parkinson's disease: neuroprotection and angiogenesis. Redox Biology. 2019. ↩︎
Chu J, Guo J, Liu Y, et al. VEGF and ischemic stroke: molecular mechanisms and therapeutic potential. Journal of Molecular Neuroscience. 2019. ↩︎
Katusic ZS, Austin SA. Endothelial nitric oxide: protector of optic nerve and brain. Translational Research. 2019. ↩︎
Xiao T, Chen Y, Liu J, et al. Therapeutic targeting of VEGF signaling in neurodegenerative diseases. Advanced Drug Delivery Reviews. 2021. ↩︎
Tian M, Chen Y, Chen S, et al. KDR modulation and therapeutic potential in Alzheimer's disease. Journal of Alzheimer's Disease. 2022. ↩︎